|
Categories
Pharmaceutical Company
Pharmaceutical Sales
Pharmaceutical
Distributor
Pharmaceutical
Preparation
Pharmaceutical
Jobs
Pharmaceutical
Industry
Pharmaceutical
Drug
Pharmaceutical
Sales Jobs
Pharmaceutical
Product
Pharmaceutical
News
Pharmaceutical
Research
Pharmaceutical
Manufacturer
Pharmaceutical Sales
Rep
Pharmaceutical
Sales Resume
Pharmaceutical
Online
Pharmaceutical
Marketing
Pharmaceutical
Dictionary
Pharmaceutical
Recruiter
Pharmaceutical
Supply
Pharmaceutical
Technology
Pharmaceutical
Advertising
Pharmaceutical
Schools
Companies
Pfizer Pharmaceutical
Wyeth Pharmaceutical
Watson Pharmaceutical
Merck Pharmaceutical
Roche Pharmaceutical
King Pharmaceutical
Teva Pharmaceutical
Aventis
Pharmaceutical
Novartis
Pharmaceutical
Forest
Pharmaceutical
Tap
Pharmaceutical
Shire
Pharmaceutical
Mayne
Pharmaceutical
Millennium
Pharmaceutical
Lilly
Pharmaceutical
Mylan
Pharmaceutical
Kos
Pharmaceutical
Takeda
Pharmaceutical
Endo
Pharmaceutical
Janssen
Pharmaceutical
Barr
Pharmaceutical
Abbott
Pharmaceutical
Reliant
Pharmaceutical
Solvay
Pharmaceutical
Amylin
Pharmaceutical
Vertex
Pharmaceutical
Osi
Pharmaceutical
Bayer
Pharmaceutical
Voyager
Pharmaceutical
Mcneil
Pharmaceutical
Boehringer
Ingelheim
Astra
Zeneca Pharmaceutical
Glaxosmithkline
Pharmaceutical
Novo Nordisk
Pharmaceutical
3m
Pharmaceutical
Eli
Lilly Pharmaceutical
Elan Pharmaceutical
Ivax
Pharmaceutical
Search engines:
Google
Lycos
AltaVista
Yahoo
Mirago
Ask
Teoma
Excite |
|
|
|
Shire Pharmaceutical
 Shire
Pharmaceutical
Shire is a rapidly growing global specialty
pharmaceutical company. The Group has a global sales and marketing
infrastructure with a broad portfolio of products and its own direct marketing
capability in the US, Canada, UK, Republic of Ireland, France, Germany, Italy
and Spain. Shire also covers the other significant pharmaceutical markets
indirectly through distributors. Shire’s interest in the Pacific Rim is
managed through Shire’s regional office based in Singapore. M&A
activity of the Group during the last several years has resulted in six
completed mergers and acquisitions.
To enhance the potential for future
growth Shire is actively searching to acquire further development projects as
well as marketed products and continues to evaluate M&A opportunities that
offer a good strategic fit and add shareholder value.
Shire
Pharmaceutical - history
Today Shire is one of the world’s
fastest growing specialty pharmaceutical companies. Fourteen years ago it was a
tiny business. Since then it has increased its value to $5billion.
Shire
was founded and funded in 1986 in the UK by four entrepreneurs (Dennis
Stephens, Harry Stratford, Peter Moriarty, and Geoff Hall). Each had
considerable experience either in or directly serving the pharmaceutical
industry. The company, initially launched and sold a range of calcium products
designed to help with the bone disease, osteoporosis (Calcichew is still one of
Shire’s successfully marketed products). The company, originally named
AimCane, began in a small office above a shop in Hampshire in the UK –
indeed, the company soon changed its name to Shire which came from the name of
the building that housed the company in those early days.
Shire
expanded its specialism to include hormone replacement therapy (HRT) and
Alzheimer’s disease and acquired the rights to galantamine – as well
as developing a partnership with Janssen to develop this product into what is
now known as Reminyl, Shire’s multi-million pound Alzheimer’s
product.
From the very early days, Shire concentrated on developing
personal relationships with hospital doctors and specialists – a
cornerstone in the company’s strategy that remains today.
The
company began trading fully in 1987 and in 1995 it made its first acquisition
of Imperial Pharmaceutical Services, another business based in Hampshire. This
acquisition brought to Shire a range of product licenses as well as capital
that enabled the company to embark on expansion and a series of further
acquisitions.
The Company was floated on the London Stock Exchange in
February 1996. This was a significant moment in the company’s history as
it reflected the Shire ambitions to invest, to expand and to become an
international force in the industry while still retaining a point of difference
from the other big pharmaceutical giants.
Since this time, Shire’s
growth has been fuelled by acquisitions – there were six acquisitions in a
six year period. Each merger or acquisition brought new products, new expertise
and new strengths to the organisation as well as contributing towards the
building of the multinational company that Shire now is.
In 1997, the
Pharmavene acquisition brought the expertise of drug delivery development into
the Shire fold. This led to the creation of Shire Laboratories, our company in
the United States, which excels at developing new ways of delivering medicines
– such as our successful once daily formulations for Carbatrol and
Adderall.
A further US acquisition of Richwood in the same year added
marketing and sales to Shire’s organisation as well as bringing us the
rights to the attention deficit and hyperactivity disorder product, Adderall.
In one year, the company was transformed into a global player with a
significant presence in the United States, the largest pharmaceutical market in
the world. Shire needed to increase its infrastructure in Europe and in 1999 it
bought Fuisz and Roberts. This created a Shire network in France, Germany and
Italy as well as adding important new products (Agrylin and Lodine) in cancer
and gastro intestinal disorders.
In 2001 Shire merged with Canadian
pharmaceutical company, Biochem Pharma. This move added a very diverse
portfolio of products including the world’s leading HIV/Aids treatment
3TC.
Most recently, Shire announced that it would focus the business on
the search, development and marketing of products in areas where it can compete
effectively. The company does not undertake its own early stage research;
Shire’s focus is on the development of later stage products in phase II or
beyond.
Shire is now the third largest pharmaceutical company in the UK
and one of the fastest growing specialty companies in the world, it is the
market leader in attention deficit and hyperactivity disorder in the United
States, it has a growing European network and an exciting set of products that
are being developed for launch and marketing in the future.
Shire has an
interesting past but a very exhilarating future ahead. Shire’s aim is to
become one of the world’s leading specialty pharmaceutical companies
– number one for products, number one for customer care, number one for
profitability and number one for people.
Shire - further
information
www.shire.com
Page last updated:
27/04/06 |
|
|
|
|
